ReviewNature neuroscience2016
The road to precision psychiatry: translating genetics into disease mechanisms.
Review in Nature neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- Differentiation between bipolar disorder and major depressive disorder in adolescents: from clinical to biological biomarkers.Frontiers in human neuroscience · 2023Pooled it
- κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine.Journal of clinical psychopharmacologyTrial
- Upregulation of circSUCO22-20 in schizophrenia: clinical correlation with systemic inflammation and in vitro pro-apoptotic mechanisms.European archives of psychiatry and clinical neuroscience · 2026Article
- Tutorial: interrogating biology using organoid technologies.Nature protocols · 2026Review
- Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.Nature genetics · 2026Article
- Comparative Efficacy and Acceptability of Non-pharmacological Therapies and Novel Pharmacotherapies for Autism: A Systematic Review and Network Meta-Analysis.Child psychiatry and human development · 2026Review
- Dynamic Fusion of Genomics and Functional Network Connectivity in UK Biobank Reveals Schizophrenia-Related SNP Manifolds.Human brain mapping · 2026Article
- Does genetic testing impact stigma in autism: A scoping review.Journal of community genetics · 2026Review
- Altered core depressive symptom balance in post-COVID fatigue: reduced depressed mood in an exploratory matched historical-control study.Frontiers in psychiatry · 2026Article
- Disrupted genes and pathways in schizophrenia: a robust analysis of the brain and blood.BMC psychiatry · 2025Article
- Review
- Integrating genetic regulation and schizophrenia-specific splicing quantitative expression with GWAS prioritizes novel risk genes for schizophrenia.Translational psychiatry · 2025Article
- Mediating Role of Trauma Connecting Psychiatric Family History and Adolescent Mental Health.Biological psychiatry global open science · 2025Article
- Integrative multi-omics data from early development to identify the genes and cell types underlying attention-deficit/hyperactivity disorder.BMC psychiatry · 2025Article
- Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025Review
- Carbamoylated Erythropoietin Rescues Autism-Relevant Social Deficits in BALB/cJ Mice.NeuroSci · 2025Article
- A Multi-omic study integrating plasma protein, multiple tissues, and single-cell identifies RNASET2 as a key gene for lung cancer.Discover oncology · 2025Article
- Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders.JAMA psychiatry · 2025Article
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Sleep on it: exploring the psychology of sleep amidst contemporary challenges.Scientific reports · 2024Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Hundreds of genetic loci increasing risk for neuropsychiatric disorders have recently been identified. This success, perhaps paradoxically, has posed challenges for therapeutic development, which are amplified by the highly polygenic and pleiotropic nature of these genetic contributions. Success requires understanding the biological impact of single genetic variants and predicting their effects within an individual. Comprehensive functional genomic annotation of risk loci provides a framework for interpretation of neurobiological impact, requiring experimental validation with in vivo or in vitro model systems. Systems-level, integrative pathway analyses are beginning to elucidate the additive, polygenic contributions of risk variants on specific cellular, molecular, developmental, or circuit-level processes. Although most neuropsychiatric disease modeling has focused on genes disrupted by rare, large-effect-size mutations, common smaller-effect-size variants may also provide solid therapeutic targets to inform precision medicine approaches. Here we enumerate the promise and challenges of a genomics-driven approach to uncovering neuropsychiatric disease mechanisms and facilitating therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.